Abstract:Compared with traditional chemotherapy and radiation therapy, immune checkpoint inhibitors (ICIs) exhibit better efficacy and lower side effects on many cancers, especially monoclonal antibodies (mAbs) targeting programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1). At present, many related drugs such as nivolumab, pembrolizumab, cemiplimab-rwlc, atezolizumab, avelumab and durvalumab have been widely used in clinic, while drug resistance and toxicity are the two major factors that have limited their use. For this case, the results of several clinical trials have shown significant improvements with combination treatment strategies compared to monotherapy.

PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond